What's Happening?
The pharmaceutical industry is increasingly integrating artificial intelligence (AI) into its operations, moving beyond pilot projects to become a core component of healthcare and pharmaceutical processes. A new white paper from BioPhorum, titled 'A Practical
Guide to Technical Assurance for AI,' highlights the need for robust technical assurance to build trust in AI systems. The paper argues that while the industry is familiar with structural and process assurance, technical assurance is crucial for ensuring AI models perform reliably in real-world conditions. This involves gathering empirical evidence on model performance, robustness, bias behavior, explainability, and drift control. The paper outlines four assurance layers—structural, process, technical, and cultural—that together form a comprehensive trust architecture for AI in pharma.
Why It's Important?
The integration of AI in the pharmaceutical industry holds significant potential for improving efficiency and innovation. However, without proper technical assurance, AI systems may pose risks, such as unreliable performance or biased outcomes, which could have serious implications for patient safety and regulatory compliance. By emphasizing technical assurance, the industry aims to ensure that AI systems are not only compliant but also stable and safe in practice. This shift is crucial as AI becomes more embedded in high-consequence environments, where errors can have significant impacts on public health and safety. Ensuring AI systems are dependable and defensible will help the industry keep pace with emerging regulations and maintain public trust.
What's Next?
As AI continues to be integrated into pharmaceutical operations, companies will need to adopt a mindset shift towards evidence-based trust in AI systems. This involves building cross-functional AI assurance teams, maintaining auditable AI assurance registers, and embedding technical assurance into vendor contracts. Organizations will also need to focus on continuous monitoring and retraining of AI systems to manage data and concept drift. By doing so, they can ensure that AI systems remain reliable and effective over time, even as conditions change. This proactive approach will be essential for navigating the evolving regulatory landscape and ensuring the safe and effective use of AI in the pharmaceutical industry.
